Disclosures for "Final Cerebral Infarct Volume in Acute Ischemic Stroke – Is It Different Among Diabetics Treated with Tenecteplase vs. Alteplase?"
-
Miss Mohammed has nothing to disclose.
-
Dr. Hegde has nothing to disclose.
-
Roberto Hernandez has nothing to disclose.
-
Dr. Salter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gryphon Bio. Dr. Salter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abata Therapeutics. Dr. Salter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sora Neuroscience. Dr. Salter has stock in Owl Therapeutics. The institution of Dr. Salter has received research support from National Multiple Sclerosis Society. The institution of Dr. Salter has received research support from Department of Defense Congressionally Directed Medical Research Program. The institution of Dr. Salter has received research support from Consortium of Multiple Sclerosis Centers.
-
Dr. Ray has nothing to disclose.